Imai Shunsuke, Nakamura Masaki, Chujo Satomi, Ooki Ryousuke, Inoue Yasushi, Horiuchi Hajime, Morikawa Teppei, Uchino Keita, Igarashi Atsuyuki, Shiga Yoshiyuki
Urology NTT Medical Center Tokyo Tokyo Japan.
Department of Dermatology NTT Medical Center Tokyo Tokyo Japan.
IJU Case Rep. 2021 Aug 5;4(6):386-390. doi: 10.1002/iju5.12356. eCollection 2021 Nov.
The combination of pembrolizumab and axitinib has recently been approved as a first-line treatment for previously untreated metastatic renal cell carcinoma. However, immune-related adverse events are not well known.
A 65-year-old male was diagnosed with renal cell carcinoma with metastases to the brain and lungs. The patient had a medical history of stasis dermatitis. During the combined treatment of pembrolizumab and axitinib, blisters appeared on the lower extremities. Skin biopsy revealed septal panniculitis, pustules, and perivascular lymphocytic and neutrophilic infiltration of the skin, and the patient was diagnosed with immune-related dermatitis. The dermatitis improved with oral prednisolone treatment.
A case of immune-related dermatitis during combinatorial treatment with pembrolizumab and axitinib for renal cell carcinoma has been reported. Preexisting stasis dermatitis may have affected the onset and deterioration of immune-related dermatitis.
帕博利珠单抗和阿昔替尼联合用药最近已被批准作为既往未接受过治疗的转移性肾细胞癌的一线治疗方案。然而，免疫相关不良事件尚不为人们所熟知。
一名65岁男性被诊断为肾细胞癌伴脑和肺转移。该患者有淤积性皮炎病史。在帕博利珠单抗和阿昔替尼联合治疗期间，患者双下肢出现水疱。皮肤活检显示间隔性脂膜炎、脓疱以及皮肤血管周围淋巴细胞和中性粒细胞浸润，该患者被诊断为免疫相关性皮炎。经口服泼尼松龙治疗后，皮炎症状有所改善。
本文报告了一例在使用帕博利珠单抗和阿昔替尼联合治疗肾细胞癌过程中发生免疫相关性皮炎的病例。既往存在的淤积性皮炎可能影响了免疫相关性皮炎的发生和病情恶化。
